CD274 and triple-negative breast carcinoma: For example, pembrolizumab is approved as monotherapy in metastatic NSCLC patients with PD-L1 >50% (TPS), while investigators in Impassion130, for example, used PD-L1 (TPSS) ≥1% as a cut-off that showed OS benefit to atezolizumab treatment of triple-negative breast cancer [140,141].